{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:27:17Z","timestamp":1780417637749,"version":"3.54.1"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Therapeutic drugs can sometimes cause adverse effects in a nonclinical species that do not translate to other species, including human. Species-specific (rat, dog, and human) in vitro liver spheroids were employed to understand the human relevance of cholestatic liver injury observed with a selective estrogen receptor degrader (amcenestrant) in dog, but not in rat, during preclinical development. Amcenestrant showed comparable cytotoxicity in liver spheroids from all 3 species; however, its M5 metabolite (RA15400562) showed dog preferential cytotoxicity after 7\u00a0days of treatment. Whole genome transcript profiles generated from liver spheroids revealed downregulation of genes related to bile acid synthesis and transport indicative of strong farnesoid X receptor (FXR) antagonism following treatment with both amcenestrant and its M5 metabolite in the dog but not in rat or human. In human spheroids, upregulation of genes for detoxification enzymes indicative of pregnane X receptor (PXR) agonism was observed following amcenestrant treatment, whereas in the dog these genes were downregulated. The M5 metabolite showed gene dysregulation indicating PXR agonism in both rat and human, and antagonism in dog. Analysis of liver samples from a 3-mo dog toxicity study conducted with amcenestrant showed downregulation of several genes associated with PXR and FXR, corroborating the in vitro results. These results support the hypothesis that dogs are uniquely susceptible to cholestatic hepatotoxicity following administration of amcenestrant due to species-specific antagonism of FXR and highlight the value of in vitro liver spheroids to investigating mechanisms of toxicity and possible species differences.<\/jats:p>","DOI":"10.1093\/toxsci\/kfaf012","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:56:36Z","timestamp":1738324596000},"page":"228-241","source":"Crossref","is-referenced-by-count":3,"title":["Transcriptomic analysis in liver spheroids identifies a dog-specific mechanism of hepatotoxicity for amcenestrant"],"prefix":"10.1093","volume":"204","author":[{"given":"Piyush","family":"Bajaj","sequence":"first","affiliation":[{"name":"Global Investigative Toxicology, Preclinical Safety, Sanofi , Cambridge, MA 02141,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0449-2730","authenticated-orcid":false,"given":"Richard J","family":"Brennan","sequence":"additional","affiliation":[{"name":"Global Investigative Toxicology, Preclinical Safety, Sanofi , Cambridge, MA 02141,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Laurent","sequence":"additional","affiliation":[{"name":"Preclincial Safety, Sanofi , Montpellier 34070,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Sauzeat","sequence":"additional","affiliation":[{"name":"Preclincial Safety, Sanofi , Montpellier 34070,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dufault","sequence":"additional","affiliation":[{"name":"Precision Medicine and Computational Biology, Sanofi , Cambridge, MA 02141,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Richards","sequence":"additional","affiliation":[{"name":"Genetic Medicine Unit, Sanofi , Waltham, MA 02451,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Adkins","sequence":"additional","affiliation":[{"name":"Global Investigative Toxicology, Preclinical Safety, Sanofi , Cambridge, MA 02141,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2025032706240942200_kfaf012-B1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep.26055","article-title":"Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype","volume":"57","author":"Abu-Hayyeh","year":"2013","journal-title":"Hepatology"},{"key":"2025032706240942200_kfaf012-B2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025032706240942200_kfaf012-B3","doi-asserted-by":"crossref","first-page":"9737920","DOI":"10.1155\/2016\/9737920","article-title":"Key challenges and opportunities associated with the use of in vitro models to detect human DILI: integrated risk assessment and mitigation plans","volume":"2016","author":"Atienzar","year":"2016","journal-title":"Biomed Res Int"},{"key":"2025032706240942200_kfaf012-B4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.therap.2018.02.004","article-title":"Safety data and withdrawal of hepatotoxic drugs","volume":"76","author":"Babai","year":"2021","journal-title":"Therapie"},{"key":"2025032706240942200_kfaf012-B5","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1038\/s41467-022-31668-8","article-title":"AMEERA-1 phase 1\/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive\/HER2-negative advanced breast cancer","volume":"13","author":"Bardia","year":"2022","journal-title":"Nat Commun"},{"key":"2025032706240942200_kfaf012-B6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/dmd.121.000774","article-title":"Comparison of tissue abundance of non-cytochrome P450 drug-metabolizing enzymes by quantitative proteomics between humans and laboratory animal species","volume":"50","author":"Basit","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"2025032706240942200_kfaf012-B7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/toxsci\/kfx289","article-title":"Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study","volume":"162","author":"Bell","year":"2018","journal-title":"Toxicol Sci"},{"key":"2025032706240942200_kfaf012-B8","doi-asserted-by":"crossref","first-page":"25187","DOI":"10.1038\/srep25187","article-title":"Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease","volume":"6","author":"Bell","year":"2016","journal-title":"Sci Rep"},{"key":"2025032706240942200_kfaf012-B9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/dmd.116.074369","article-title":"Transcriptional, functional and mechanistic comparisons of stem cell-derived hepatocytes, HepaRG cells and 3D human hepatocyte spheroids as predictive in vitro systems for drug-induced liver injury","volume":"45","author":"Bell","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"2025032706240942200_kfaf012-B10","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bbadis.2017.09.019","article-title":"Nuclear receptor FXR, bile acids and liver damage: introducing the progressive familial intrahepatic cholestasis with FXR mutations","volume":"1864","author":"Cariello","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2025032706240942200_kfaf012-B11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.livres.2020.05.001","article-title":"Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis","volume":"4","author":"Chiang","year":"2020","journal-title":"Liver Res"},{"key":"2025032706240942200_kfaf012-B12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s13318-020-00635-3","article-title":"Pharmacokinetic and pharmacodynamic studies of elacestrant, a novel oral selective estrogen receptor degrader, in healthy post-menopausal women","volume":"45","author":"Conlan","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2025032706240942200_kfaf012-B13","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.23.02036","article-title":"Randomized phase III study of amcenestrant plus palbociclib versus letrozole plus palbociclib in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: primary results from AMEERA-5","volume":"42","author":"Cort\u00e9s","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025032706240942200_kfaf012-B14","doi-asserted-by":"crossref","first-page":"611913","DOI":"10.3389\/fmedt.2020.611913","article-title":"Current perspective: 3D spheroid models utilizing human-based cells for investigating metabolism-dependent drug-induced liver injury","volume":"2","author":"Cox","year":"2020","journal-title":"Front Med Technol"},{"key":"2025032706240942200_kfaf012-B15","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cpt.3185","article-title":"Safety, tolerability, and pharmacokinetics of an oral small molecule inhibitor of IL-17A (LY3509754): a phase I randomized placebo-controlled study","volume":"115","author":"Datta-Mannan","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2025032706240942200_kfaf012-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.2517-6161.1977.tb01600.x","article-title":"Maximum likelihood from incomplete data via the EM algorithm","volume":"39","author":"Dempster","year":"1977","journal-title":"J R Stat Soc"},{"key":"2025032706240942200_kfaf012-B17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cpt.1615","article-title":"DNL104, a centrally penetrant ripk1 inhibitor, inhibits rip1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers","volume":"107","author":"Grievink","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2025032706240942200_kfaf012-B18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0006-291X(02)00229-2","article-title":"LXR alpha is the dominant regulator of CYP7A1 transcription","volume":"293","author":"Gupta","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"2025032706240942200_kfaf012-B19","doi-asserted-by":"crossref","first-page":"35434","DOI":"10.1038\/srep35434","article-title":"Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability","volume":"6","author":"Hendriks","year":"2016","journal-title":"Sci Rep"},{"key":"2025032706240942200_kfaf012-B20","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/cpt.1860","article-title":"Clinically relevant cytochrome P450 3A4 induction mechanisms and drug screening in three-dimensional spheroid cultures of primary human hepatocytes","volume":"108","author":"Hendriks","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2025032706240942200_kfaf012-B21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40268-023-00427-5","article-title":"Hepatotoxicity of AKR1C3 inhibitor BAY1128688: findings from an early terminated phase IIa trial for the treatment of endometriosis","volume":"23","author":"Hilpert","year":"2023","journal-title":"Drugs R D"},{"key":"2025032706240942200_kfaf012-B22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/07853890310008224","article-title":"Drug-activated nuclear receptors CAR and PXR","volume":"35","author":"Honkakoski","year":"2003","journal-title":"Ann Med"},{"key":"2025032706240942200_kfaf012-B23","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/bioinformatics\/bts294","article-title":"OSA: a fast and accurate alignment tool for RNA-seq","volume":"28","author":"Hu","year":"2012","journal-title":"Bioinformatics"},{"key":"2025032706240942200_kfaf012-B24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbadis.2011.01.014","article-title":"Nuclear receptor PXR, transcriptional circuits and metabolic relevance","volume":"1812","author":"Ihunnah","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"2025032706240942200_kfaf012-B25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bcpt.13587","article-title":"3D human liver spheroids for translational pharmacology and toxicology","volume":"130(Suppl 1)","author":"Ingelman-Sundberg","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025032706240942200_kfaf012-B26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.dmpk.2016.11.002","article-title":"Toxicological potential of acyl glucuronides and its assessment","volume":"32","author":"Iwamura","year":"2017","journal-title":"Drug Metab Pharmacokinet"},{"key":"2025032706240942200_kfaf012-B27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/aivt.2018.0011","article-title":"Cholestatic drug induced liver injury: a function of bile salt export pump inhibition and farnesoid X receptor antagonism","volume":"4","author":"Jackson","year":"2018","journal-title":"Appl In Vitro Toxicol"},{"key":"2025032706240942200_kfaf012-B28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/164_2019_231","article-title":"Targeting FXR in cholestasis","volume":"256","author":"Keitel","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"2025032706240942200_kfaf012-B29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics"},{"key":"2025032706240942200_kfaf012-B30","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1021\/acs.chemrestox.5b00315","article-title":"Toxicity of carboxylic acid-containing drugs: the role of acyl migration and CoA conjugation investigated","volume":"28","author":"Lassila","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"2025032706240942200_kfaf012-B31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/bioinformatics\/btp692","article-title":"RNA-seq gene expression estimation with read mapping uncertainty","volume":"26","author":"Li","year":"2010","journal-title":"Bioinformatics"},{"key":"2025032706240942200_kfaf012-B32","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.xphs.2020.02.021","article-title":"Three-dimensional spheroids with primary human liver cells and differential roles of Kupffer cells in drug-induced liver injury","volume":"109","author":"Li","year":"2020","journal-title":"J Pharm Sci"},{"key":"2025032706240942200_kfaf012-B33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hep.20514","article-title":"Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin","volume":"41","author":"Liguori","year":"2005","journal-title":"Hepatology"},{"key":"2025032706240942200_kfaf012-B34","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1172\/JCI18945","article-title":"Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis","volume":"112","author":"Liu","year":"2003","journal-title":"J Clin Invest"},{"key":"2025032706240942200_kfaf012-B35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025032706240942200_kfaf012-B36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/s12248-021-00590-0","article-title":"Comparison of canine and human physiological factors: understanding interspecies differences that impact drug pharmacokinetics","volume":"23","author":"Martinez","year":"2021","journal-title":"Aaps J"},{"key":"2025032706240942200_kfaf012-B37","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM199510263331702","article-title":"Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B","volume":"333","author":"McKenzie","year":"1995","journal-title":"N Engl J Med"},{"key":"2025032706240942200_kfaf012-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/aivt.2017.0022","article-title":"Transcriptomic, proteomic, and functional long-term characterization of multicellular three-dimensional human liver microtissues","volume":"4","author":"Messner","year":"2018","journal-title":"Appl In Vitro Toxicol"},{"key":"2025032706240942200_kfaf012-B39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2017.09.006","article-title":"Current nonclinical testing paradigm enables safe entry to first-in-human clinical trials: the IQ consortium nonclinical to clinical translational database","volume":"334","author":"Monticello","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"2025032706240942200_kfaf012-B40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul Toxicol Pharmacol"},{"key":"2025032706240942200_kfaf012-B41","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00280-015-2712-0","article-title":"Unexpected hepatotoxicity in a phase i study of TAS266, a novel tetravalent agonistic nanobody targeting the DR5 receptor","volume":"75","author":"Papadopoulos","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025032706240942200_kfaf012-B42","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1124\/dmd.113.052415","article-title":"Transcriptomic hepatotoxicity signature of chlorpromazine after short- and long-term exposure in primary human sandwich cultures","volume":"41","author":"Parmentier","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"2025032706240942200_kfaf012-B43","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J Gastroenterol"},{"key":"2025032706240942200_kfaf012-B44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.toxrep.2020.12.019","article-title":"Species differences in phenobarbital-mediated UGT gene induction in rat and human liver microtissues","volume":"8","author":"Plummer","year":"2021","journal-title":"Toxicol Rep"},{"key":"2025032706240942200_kfaf012-B45","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00204-017-2002-1","article-title":"Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury","volume":"91","author":"Proctor","year":"2017","journal-title":"Arch Toxicol"},{"key":"2025032706240942200_kfaf012-B46","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/bdd.720","article-title":"Acyl glucuronides: the good, the bad and the ugly","volume":"31","author":"Regan","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"2025032706240942200_kfaf012-B47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/toxsci\/kfab039","article-title":"High-throughput transcriptomic analysis of human primary hepatocyte spheroids exposed to per- and polyfluoroalkyl substances as a platform for relative potency characterization","volume":"181","author":"Rowan-Carroll","year":"2021","journal-title":"Toxicol Sci"},{"key":"2025032706240942200_kfaf012-B48","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0090-9556(25)06821-7","article-title":"Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey","volume":"23","author":"Sharer","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"2025032706240942200_kfaf012-B49","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/1535-7163.MCT-20-0390","article-title":"SAR439859, a novel selective estrogen receptor degrader (SERD), demonstrates effective and broad antitumor activity in wild-type and mutant er-positive breast cancer models","volume":"20","author":"Shomali","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2025032706240942200_kfaf012-B50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1124\/mol.118.114827","article-title":"Severe hepatotoxicity of mithramycin therapy caused by altered expression of hepatocellular bile transporters","volume":"96","author":"Sissung","year":"2019","journal-title":"Mol Pharmacol"},{"key":"2025032706240942200_kfaf012-B51","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/dmd.118.080515","article-title":"Safety assessment of acyl glucuronides \u2013 a simplified paradigm","volume":"46","author":"Smith","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"2025032706240942200_kfaf012-B52","author":"Stemline Therapeutics, Inc., a Menarini Group Company, Orserdu (Elacestrant)","year":"2023"},{"key":"2025032706240942200_kfaf012-B53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025032706240942200_kfaf012-B54","doi-asserted-by":"crossref","first-page":"151509","DOI":"10.1016\/j.scitotenv.2021.151509","article-title":"Transcriptome analysis of 3d primary mouse liver spheroids shows that long-term exposure to hexafluoropropylene oxide trimer acid disrupts hepatic bile acid metabolism","volume":"812","author":"Sun","year":"2022","journal-title":"Sci Total Environ"},{"key":"2025032706240942200_kfaf012-B55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cbi.2015.11.023","article-title":"Transcriptional profiling suggests that nevirapine and ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes","volume":"255","author":"Terelius","year":"2016","journal-title":"Chem Biol Interact"},{"key":"2025032706240942200_kfaf012-B56","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/jat.3644","article-title":"Species differences in bile acids I. Plasma and urine bile acid composition","volume":"38","author":"Thakare","year":"2018","journal-title":"J Appl Toxicol"},{"key":"2025032706240942200_kfaf012-B57","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1177\/0192623310386499","article-title":"Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system","volume":"38","author":"Thoolen","year":"2010","journal-title":"Toxicol Pathol"},{"key":"2025032706240942200_kfaf012-B58","first-page":"473","volume-title":"Medicinal chemistry reviews","author":"Tran","year":"2023"},{"key":"2025032706240942200_kfaf012-B59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2017.03.003","article-title":"Acyl glucuronide metabolites: implications for drug safety assessment","volume":"272","author":"Van Vleet","year":"2017","journal-title":"Toxicol Lett"},{"key":"2025032706240942200_kfaf012-B60","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/toxsci\/kfy058","article-title":"Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions","volume":"163","author":"Vorrink","year":"2018","journal-title":"Toxicol Sci"},{"key":"2025032706240942200_kfaf012-B61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41573-019-0048-x","article-title":"Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models","volume":"19","author":"Weaver","year":"2020","journal-title":"Nat Rev Drug Discov"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfaf012\/61706891\/kfaf012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/204\/2\/228\/61706891\/kfaf012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/204\/2\/228\/61706891\/kfaf012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T06:47:49Z","timestamp":1743317269000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/204\/2\/228\/7991300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1,30]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfaf012","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"value":"1096-6080","type":"print"},{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,30]]}}}